SER recommendations on the use of biological drugs in primary Sjogren's syndrome

Objective: To formulate SER recommendations for the use of biological agents in primary Sjogren's syndrome (pSS). Methods: Relevant clinical research questions were identified on the use of biological agents in pSS. The clinical questions were reformulated into 4 PICO questions. A search strate...

Descripción completa

Detalles Bibliográficos
Autores: Andréu Sánchez JL, Fernández Castro M, Del Campo Fontecha PD, Corominas H, Narváez García FJ, Gómez de Salazar JR, Rua-Figueroa Í, Abad Hernández MÁ, Álvarez Rivas MN, Montes JDP, Francisco Hernández FM, Gantes Pedraza MÁ, Greco Merino MG, Hernández MV, Navarro Compán MV, Solarte JAP, Romero Bueno FI, Park HS, Sivera Mascaró F
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2019
País:España
Institución:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p7247
Acceso en línea:https://fisabio.portalinvestigacion.com/publicaciones/7247
Access Level:acceso abierto
Palabra clave:Sjogren's syndrome
Biological therapy
Etanercept
Infliximab
Rituximab
Belimumab
Abatacept
Tocilizumab
Spanish Society of Rheumatology
Recommendations
Descripción
Sumario:Objective: To formulate SER recommendations for the use of biological agents in primary Sjogren's syndrome (pSS). Methods: Relevant clinical research questions were identified on the use of biological agents in pSS. The clinical questions were reformulated into 4 PICO questions. A search strategy was designed and a review of the scientific evidence of studies published until May 2017 was carried out. The scientific evidence available was systematically reviewed. The overall level of scientific evidence was assessed using the SIGN evidence levels. After that, specific recommendations were made. Results: Rituximab is recommended as the biological agent of choice for extraglandular manifestations refractory to conventional treatment. The use of anti-TNF agents is discouraged. The scientific evidence with belimumab and abatacept is scarce, so they should be considered only in cases refractory to rituximab. Conclusions: Rituximab is the biological agent of choice in severe extraglandular manifestations of pSS. Belimumab or abatacept may be useful in selected cases. (C) 2018 Elsevier Espana, S.L.U. and Sociedad Espanola de Reumatologia y Colegio Mexicano de Reumatologia. All rights reserved.

Similares en LA Referencia